Viracta Therapeutics (VIRX)

Viracta Therapeutics (VIRX) Financial Statements


Viracta Therapeutics Financial Overview

Viracta Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.319; its P/E ratio is -0.82; Viracta Therapeutics is scheduled to report earnings on May 7, 2024, and the estimated EPS forecast is $-0.36. See an overview of income statement, balance sheet, and cash flow financials.
Sep 23Jun 23Mar 23Dec 22Sep 22
Income Statement-
Total Revenue----$ 0.00
Gross Profit-----
EBIT$ -11.60M$ -11.59M$ -12.12M$ -10.76M$ -17.60M
EBITDA-$ -12.01M$ -12.52M$ -11.15M$ -17.56M
Net Income Common Stockholders$ -12.55M$ -12.48M$ -12.12M$ -10.30M$ -17.74M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 62.95M$ 72.87M$ 80.33M$ 91.04M$ 77.07M
Total Assets$ 66.44M$ 76.86M$ 85.66M$ 95.99M$ 82.20M
Total Debt$ 25.56M$ 25.55M$ 25.54M$ 25.16M$ 5.25M
Net Debt$ -37.39M$ -47.31M$ -54.79M$ -65.89M$ -71.82M
Total Liabilities$ 36.43M$ 36.08M$ 34.67M$ 34.89M$ 14.39M
Stockholders Equity$ 30.01M$ 40.78M$ 51.11M$ 61.10M$ 67.81M
Cash Flow-
Free Cash Flow-$ -8.18M$ -11.34M$ -7.90M$ -7.16M
Operating Cash Flow$ -10.54M$ -7.99M$ -11.34M$ -7.90M$ -7.16M
Investing Cash Flow$ 9.10M$ 3.98M$ -7.35M$ -203.00K$ -52.06M
Financing Cash Flow-$ 204.00K$ 16.00K$ 21.41M$ 1.10M
Currency in USD

Viracta Therapeutics Earnings and Revenue History

Viracta Therapeutics Debt to Assets

Viracta Therapeutics Cash Flow

Viracta Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis